2 results
Approved WMORecruiting
Demonstrate superiority of NEVANAC® (nepafenac ophthalmic suspension) 0.1% relative to nepafenac vehicle based on the percentage of diabetic retinopathy patients who develop macular edema (defined as >=30% increase from pre-operative baseline…
Approved WMOPending
Primary:1. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol secretion in the absence of a 5HTP-challenge.2. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol…